Ocugen reported interim Phase 2 data for its geographic atrophy gene therapy program showing positive signals from a limited patient cohort. Company statements said the candidate demonstrated tolerability and encouraging efficacy measures that could position Ocugen against incumbent therapies from Apellis and Astellas. Management acknowledged data remain preliminary and based on small numbers, but framed the findings as evidence the program may offer an improved therapeutic profile in retinal degeneration. The readout will inform dose selection and next steps toward larger trials.